PHILADELPHIA, October 22, 2013 /PRNewswire/ --
Sanofi will use QUOSA, part of Elsevier Life Science S olutions for drug discovery and development, to support adverse event monitoring
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Sanofi, one of the world's leading pharmaceutical organizations, has implemented QUOSA's literature management tools to automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and annotation of relevant case reports, allowing for the creation of a centralized repository of product-related scientific literature. This centralized repository supports Sanofi's Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient safety and compliance with regulatory reporting requirements in all the markets in which it operates.
"Pharmaceutical companies are continually challenged to ensure regulatory compliance is met. This is no easy task with limited resources, an ever-growing number of literature articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents significant risks in compliance and crucially, in patient safety," said Michael Rai, General Manager of QUOSA at Elsevier. "In response to our many conversations with Information Professionals, we have finely tuned QUOSA to complement current processes to provide a stable, efficient and scalable solution which continues to evolve with future needs. We look forward to working with Sanofi to manage this flow of information and support its Pharmacovigilance teams' work."QUOSA provides software and services to life science companies, enabling them to centralize repositories of scientific literature related to drugs and medical devices, as well as receive alerts about new articles related to their products and other market developments. These not only help Pharmacovigilance and Medical Affairs teams carry out their work effectively and quickly, they also ensure sound information management processes and compliance with regulatory requirements.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV